The Regulation of Autophagy {#S1}
===========================

Macroautophagy (herein referred to as autophagy) is an essential process for cellular homeostasis and survival of the organism. It selectively removes undesirable macromolecules or damaged organelles which might become toxic if accumulated in the cells, and non-selectively recycles cytosolic materials during starvation to generate energy ([@B104]). This process starts with the formation of isolated membrane structures in the cytoplasm called phagophores. The origin of these membrane structures has been suggested to be from the endoplasmic reticulum (ER), as well as from other sources like mitochondria, Golgi apparatus and plasma membrane ([@B184]; [@B203]). The phagophores elongate to form double membrane-bound vesicles called autophagosomes, during which the autophagic cargo is engulfed. The autophagosomes then mature to form the degradative autolysosomes either via a multi-step process by initially fusing with the late endosomes to form amphisomes and then with the lysosomes, or by directly fusing with the lysosomes ([@B106]). The autophagic cargo is eventually degraded in the autolysosomes by the acidic lysosomal enzymes and the breakdown products are then recycled ([Figure 1](#F1){ref-type="fig"}). These dynamic vesicle fusion events coupled with cargo clearance are collectively defined as autophagic flux.

![Regulation of the mammalian autophagy pathway. Autophagy initiates by the formation of phagophore that expands and engulfs autophagic cargo to form autophagosome, which then matures to form autolysosome, either by initially fusing with the late endosome to form amphisome and then with the lysosome, or by directly fusing with the lysosome. Selective autophagic cargo includes aggregation-prone proteins, damaged mitochondria, lipid droplets and glycogen, as well as the autophagy receptor protein p62; all of which are degraded in the autolysosome. Several ATG proteins including the ATG12-ATG5-ATG16L1 complex and LC3-II mediate the initiation of autophagy. LC3-II remains on the autophagosome throughout its lifespan and is thus used as a marker for autophagy. The classical regulator of autophagy is mTORC1, which negatively regulates autophagy by inhibiting the ULK1 complex. However, AMPK can positively regulate autophagy by directly phosphorylating ULK1. The mTORC1-independent regulators of autophagy include elevated intracellular levels of IP~3~, Ca^2+^, and cAMP; all of which are autophagy inhibitory signals. Autophagosome maturation in the late stage of autophagy is governed by various factors including SNAREs, HOPS complex, Rab7, GABARAPs, and ATG14L, amongst others. Autophagy can be induced pharmacologically by mTOR inhibitors (rapamycin, torin1), as well as by mTOR-independent inducers such as via AMPK activators (trehalose), and via agents lowering IP~3~ (carbamazepine), Ca^2+^ (verapamil, felodipine), and cAMP (rilmenidine) levels (reduction in second messenger molecules indicated by red arrows). Abbreviations - AMPK, 5′ adenosine monophosphate-activated protein kinase; ATG, Autophagy related; Ca^2+^, Calcium; cAMP, 3′,5′-cyclic adenosine monophosphate; FIP200, FAK family kinase-interacting protein of 200 kDa; GABARAP, γ-aminobutyric acid receptor-associated protein; HOPS, Homotypic fusion and protein sorting complex; IP~3~, Inositol 1,4,5-trisphosphate; mTORC1, Mechanistic target of rapamycin complex 1; SNARE, Soluble N-ethylmaleimide-sensitive factor activating protein receptor.](fcell-07-00179-g001){#F1}

The classical mechanism regulating autophagy is via the mechanistic target of rapamycin complex 1 (mTORC1) pathway, which negatively regulates this process under nutrient-rich conditions ([@B63]). The levels of growth factors, amino acids and energy status in the cell can also influence autophagy via mTORC1 ([@B100]). Physiologically, autophagy is stimulated by starvation via inhibition of mTORC1. Downstream of mTORC1, autophagy initiation is mediated via the ULK1 complex comprising of ULK1, FIP200, ATG13, and ATG101 ([@B205]). A positive regulator of autophagy is AMPK, which acts by either inhibiting mTORC1 or by directly inducing autophagy initiation via phosphorylation of ULK1 ([@B141]; [Figure 1](#F1){ref-type="fig"}). Another downstream target of mTOR that indirectly prevents autophagy is the phosphorylation and cytoplasm sequestration of TFEB, which is a transcription factor mediating the expression of genes related to lysosomal function ([@B159]). Apart from mTORC1-dependent regulation, autophagy can also be governed by mTORC1-independent pathways such as increase in the levels of intracellular inositol, IP~3~, Ca^2+^, cAMP and nitric oxide that negatively regulate this process ([@B144]; [Figure 1](#F1){ref-type="fig"}). Several autophagy-related (ATG) proteins in the autophagic machinery mediate the autophagy initiation steps, such as the ATG12-ATG5-ATG16L1 complex and phosphatidylethanolamine-conjugated LC3-II; the latter remains associated with the autophagosomes throughout their lifespan and acts as a marker of autophagy ([@B105]; [@B69]). After autophagosome biogenesis, their lysosomal delivery and fusion are mediated by various factors including SNAREs (syntaxin 17 and SNAP29 on autophagosomes, and lysosomal VAMP8), HOPS (homotypic fusion and protein sorting) complex, Rab7, GABARAPs, BRUCE, and Beclin1-interacting partners such as ATG14L and UVRAG ([@B190]; [@B134]; [Figure 1](#F1){ref-type="fig"}).

Since autophagy is implicated in myriad human diseases, small molecule autophagy modulators have potential biomedical relevance ([@B139]; [@B144]; [@B119]). Autophagy can be modulated pharmacologically either via inhibiting mTORC1 or independently of mTORC1. The commonly-used mTOR inhibitors for inducing autophagy are rapamycin ([@B12]) and its ester analog CCI-779 ([@B133]), and Torin 1 ([@B181]). There are several ways of inducing mTOR-independent autophagy, such as with carbamazepine (inositol lowering agent) ([@B148]), trehalose (AMPK activator) ([@B146]; [@B28]), rilmenidine (cAMP reducing agent) ([@B195]), verapamil and felodipine (Ca^2+^ channel blockers) ([@B195]; [@B161]), amongst others ([Figure 1](#F1){ref-type="fig"}). Additional means include the autophagy-inducing peptide, Tat-Beclin 1 ([@B160]). From a clinical perspective, since mTOR regulates critical cellular processes such as protein translation and cell growth, inducing autophagy independent of mTOR is considered to be a safer approach with lesser side-effects for biomedical applications ([@B139]; [@B144]).

The Role of Autophagy in Macromolecule Storage Disorders {#S2}
========================================================

An imbalance between the production and clearance of macromolecules, causing their intracellular accumulation, can lead to a category of diseases broadly known as macromolecule storage disorders. Autophagy is a major clearance route for a wide spectrum of macromolecules such as proteins, lipids and carbohydrates, either via non-selective bulk degradation or selectively via aggrephagy (for aggregated proteins), lipophagy (for lipids), and glycophagy (for glycogen) ([@B172]; [@B44]). Decline in the functionality of autophagy contributes to the build-up of macromolecular materials that could be deleterious to the cells. Indeed, impairment in autophagic flux has been reported in a number of macromolecule storage disorders ([Table 1](#T1){ref-type="table"}). In these conditions, the defect in autophagy could occur at distinct stages: inhibition in the early stages related to autophagosome formation, or impairment in the late stages involving autophagosome maturation, lysosomal function and autophagic cargo clearance ([Figure 2](#F2){ref-type="fig"}). Since autophagy is a vital homeostatic mechanism, compromised autophagy reduces cell viability and contributes to the disease pathology ([@B48]; [@B54]). Of biomedical relevance, pharmacological induction of autophagy has been shown to improve cell viability and exert beneficial effects in transgenic animal models of some macromolecular storage disorders where the lysosomal functionality is not overtly compromised ([Table 1](#T1){ref-type="table"}; [@B139]; [@B144]; [@B76]; [@B158]; [@B119]). We will discuss below the role of autophagy in few macromolecular storage disorders and highlight the potential therapeutic benefits of autophagy enhancers in these conditions.

###### 

Defective autophagy in macromolecule storage disorders and therapeutic benefits with autophagy inducers.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Mutant proteins**                          **Autophagy defects and mechanisms**                                                                                                                                                                                                                 **Autophagy inducers and their mechanisms of action**                                              **Therapeutic benefits *in vivo* or in iPSC models**
  -------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Proteinopathies**                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Alzheimer's disease (AD) and tauopathy**                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                       

  PS1\                                         Defective autophagy due to impaired autophagosome maturation; mechanism via impairment in lysosomal acidification due to improper lysosomal targeting of v-ATPase V~0~a~1~ subunit ([@B75]; [@B197])\                                                Rapamycin: Induces autophagy by mTORC1 inhibition ([@B12])                                         AD mice (*APP/Tau/PS1 mutant*) ([@B19]; [@B89]), AD mice (*APP/PS1 mutant*) ([@B56]), AD mice (*APP mutant*) ([@B169]), AD mice (*APOE4 mutant*) ([@B81]), FTD mice (*TDP-43*) ([@B189]), FTD mice (*tau mutant*) ([@B118]; [@B57]; [@B163]), FTD *Drosophila* ([@B9])
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  \                                            Defective autophagy possibly due to impaired autophagosome maturation; mechanism via disruption of axonal transport ([@B88]; [@B17])\                                                                                                                                                                                                                   
  \                                                                                                                                                                                                                                                                                                                                                                                                    
  \                                                                                                                                                                                                                                                                                                                                                                                                    
  \                                                                                                                                                                                                                                                                                                                                                                                                    
  \                                                                                                                                                                                                                                                                                                                                                                                                    
  Tau                                                                                                                                                                                                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                                                                    Carbamazepine: Induces mTOR-independent autophagy by lowering inositol and IP~3~ ([@B148])         AD mice (*APP/PS1 mutant*) ([@B179]), AD mice (*APP/Tau/PS1 mutant*) ([@B207]), FTD mice (*TDP-43*) ([@B189])\

                                                                                                                                                                                                                                                                                                    Trehalose: Induces mTOR-independent autophagy via AMPK activation ([@B146]; [@B28])                AD mice (*APP/PS1 mutant*) ([@B31]), AD mice (*APP mutant*) ([@B127]), FTD mice (*tau mutant*) ([@B135]; [@B154])\

                                                                                                                                                                                                                                                                                                    Latrepirdine: Induces autophagy by inhibition of mTORC1 signaling ([@B170])                        AD mice (*APP mutant*) ([@B170])

                                                                                                                                                                                                                                                                                                    Gypenoside XVII (GP-17): Induces autophagy by TFEB nuclear translocation ([@B101])                 AD mice (*APP/PS1 mutant*) ([@B101])

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Parkinson's disease (PD)**                                                                                                                                                                                                                                                                                                                                                                         

                                                                                                                                                                                                                                                                                                                                                                                                       

  α-syn                                        α-syn overexpression causes defective autophagy due to impaired autophagosome formation; mechanism via ATG9 mislocalization ([@B196]) and cytoplasmic retention of TFEB ([@B29]); whereas A53T and A30P α-syn mutants impair CMA ([@B25]; [@B94])\   Rapamycin: Induces autophagy by mTORC1 inhibition ([@B12])                                         PD mice (*A53T*α*-syn*) ([@B5]), PD mice (MPTP treated) ([@B90]; [@B83]), PD mice (6-OHDA treated) ([@B96]), PD mice (L-DOPA treated) ([@B143])\

  \                                            \                                                                                                                                                                                                                                                    Felodipine: Induces mTOR-independent autophagy by lowering cytosolic Ca^2+^ ([@B161])              PD mice (*A53T*α*-syn*), A53T α-syn iPSC-derived neurons ([@B161])
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  Parkin, PINK1                                Defective mitophagy due to impaired targeting of damaged mitochondria to autophagosomes ([@B46]; [@B107])                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                    6-Bio: Induces autophagy by inhibition of mTORC1 signaling ([@B174])                               PD mice (MPTP treated) ([@B174])\
                                                                                                                                                                                                                                                                                                                                                                                                       \

                                                                                                                                                                                                                                                                                                    Piperlongumine: Induces autophagy by Bcl2 phosphorylation and Bcl2-Beclin1 dissociation ([@B82])   PD mice (rotenone treated) ([@B82])

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Huntington's disease (HD)**                                                                                                                                                                                                                                                                                                                                                                        

                                                                                                                                                                                                                                                                                                                                                                                                       

  HTT                                          Defective autophagy due to impaired recognition of autophagic cargo ([@B95]) and disrupted axonal transport ([@B198])                                                                                                                                Rapamycin, CCI-779: Induces autophagy by mTORC1 inhibition ([@B12]; [@B133])                       HD mice (*HD-N171--82Q*) ([@B133]), HD *Drosophila* ([@B133]; [@B150]), HD zebrafish ([@B195])

                                                                                                                                                                                                                                                                                                    Trehalose: Induces mTOR-independent autophagy via AMPK activation ([@B146]; [@B28])                HD mice (*HD-ex1--145Q*) ([@B177])^a^\
                                                                                                                                                                                                                                                                                                                                                                                                       \
                                                                                                                                                                                                                                                                                                                                                                                                       \

                                                                                                                                                                                                                                                                                                    Rilmenidine: Induces mTOR-independent autophagy by lowering cAMP ([@B195])                         HD mice (*HD-N171--82Q*) ([@B138])\
                                                                                                                                                                                                                                                                                                                                                                                                       \
                                                                                                                                                                                                                                                                                                                                                                                                       \

                                                                                                                                                                                                                                                                                                    Felodipine: Induces mTOR-independent autophagy by lowering cytosolic Ca^2+^ ([@B161])              HD mice (*HD-N171--82Q*), HD zebrafish ([@B161])\
                                                                                                                                                                                                                                                                                                                                                                                                       \

                                                                                                                                                                                                                                                                                                    SMER28: Induces mTOR-independent autophagy ([@B147]); mechanism not known                          HD *Drosophila* ([@B147])\
                                                                                                                                                                                                                                                                                                                                                                                                       \
                                                                                                                                                                                                                                                                                                                                                                                                       \

                                                                                                                                                                                                                                                                                                    AUTEN-67, AUTEN-99: Induce autophagy by MTMR14 inhibition ([@B11]; [@B68])                         HD *Drosophila* ([@B11]; [@B68])\
                                                                                                                                                                                                                                                                                                                                                                                                       \

                                                                                                                                                                                                                                                                                                    L-NAME: Induce mTOR-independent autophagy by NOS inhibition ([@B149])                              HD *Drosophila*, HD zebrafish ([@B149])\
                                                                                                                                                                                                                                                                                                                                                                                                       \
                                                                                                                                                                                                                                                                                                                                                                                                       \

                                                                                                                                                                                                                                                                                                    Verapamil: Induces mTOR-independent autophagy by lowering cytosolic Ca^2+^ ([@B195])               HD *Drosophila*, HD zebrafish ([@B195])

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Lipid storage disorders**                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Niemann Pick type C disease (NPC)**                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                       

  NPC1                                         Defective autophagy due to impaired autophagosome maturation; mechanism via failure in SNARE machinery ([@B145]), reduction in SphK activity, and VEGF levels ([@B73])                                                                               Rapamycin: Induces autophagy by mTORC1 inhibition ([@B12])                                         NPC1 iPSC-derived neurons and hepatic cells ([@B86])

  \                                            \                                                                                                                                                                                                                                                    Carbamazepine: Induces mTOR-independent autophagy by lowering inositol and IP~3~ ([@B148])         NPC1 iPSC-derived neurons and hepatic cells ([@B86])
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  NPC2                                         Defective autophagy possibly due to impaired autophagosome maturation ([@B50]); mechanism not known                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                    Trehalose: Induces mTOR-independent autophagy via AMPK activation ([@B146]; [@B28])                NPC1 iPSC-derived neurons ([@B86])\

                                                                                                                                                                                                                                                                                                    Verapamil: Induces mTOR-independent autophagy by lowering cytosolic Ca^2+^ ([@B195])               NPC1 iPSC-derived neurons ([@B86])\

                                                                                                                                                                                                                                                                                                    BRD5631: Induces mTOR-independent autophagy ([@B70]); mechanism not known                          NPC1 iPSC-derived neurons ([@B70])

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Gaucher's disease (GD)**                                                                                                                                                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                                                                                                                                                       

  GCase                                        Defective autophagy possibly due to impaired autophagosome maturation ([@B173]); mechanism not known but suggested via lysosomal defect ([@B117])                                                                                                    Rapamycin: Induces autophagy by mTORC1 inhibition ([@B12])                                         GD *Drosophila* ([@B64])^b^

  Sap C                                        Defective autophagy possibly due to impaired autophagosome maturation; mechanism not clear but suggested via inefficient cathepsin activity ([@B180])                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Fabry disease (FD)**                                                                                                                                                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                       

  α-Gal A                                      Defective autophagy possibly due to impaired autophagosome maturation ([@B20]); mechanism not known                                                                                                                                                  Not tested                                                                                         Not tested

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Glycogen storage disorders**                                                                                                                                                                                                                                                                                                                                                                       

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Lafora disease (LD)**                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                       

  Laforin\                                     Defective autophagy due to impaired autophagosome formation; mechanism via mTOR activation ([@B1])\                                                                                                                                                  Metformin: Induces autophagy by AMPK activation ([@B18])                                           LD mice (*Epm2a^--/--^*) ([@B10])^c^
  \                                            \                                                                                                                                                                                                                                                                                                                                                       
  \                                            Defective autophagy due to impaired autophagosome formation ([@B24]); mechanism not known                                                                                                                                                                                                                                                               
  \                                                                                                                                                                                                                                                                                                                                                                                                    
  \                                                                                                                                                                                                                                                                                                                                                                                                    
  Malin                                                                                                                                                                                                                                                                                                                                                                                                

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Von Gierke's disease (GSDIa)**                                                                                                                                                                                                                                                                                                                                                                     

                                                                                                                                                                                                                                                                                                                                                                                                       

  G6PC                                         Defective autophagy due to impaired autophagosome formation; mechanism via mTOR activation, AMPK inhibition ([@B35]), SIRT1 downregulation ([@B21])                                                                                                  Rapamycin: Induces autophagy by mTORC1 inhibition ([@B12])\                                        GSDIa mice (*G6pc^--/--^*) ([@B35], [@B36]); GSDIa dogs ([@B35])\
                                                                                                                                                                                                                                                                                                    \                                                                                                  \
                                                                                                                                                                                                                                                                                                    Bezafibrate: PPAR agonist but autophagy-inducing mechanism not clear ([@B193])                     GSDIa mice (*G6pc^--/--^*) ([@B193])

                                                                                                                                                                                                                                                                                                                                                                                                       

  **Pompe disease (GSDII)**                                                                                                                                                                                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                       

  GAA                                          Defective autophagy possibly due to impaired autophagosome maturation ([@B129]; [@B108]); mechanism not known                                                                                                                                        Rapamycin: Induces autophagy by mTORC1 inhibition ([@B12])                                         GSDII mice (*Gaa^--/--^*) ([@B3])
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, Alzheimer's disease; AMPK, 5′ adenosine monophosphate-activated protein kinase; APP, Amyloid precursor protein; AUTEN, Autophagy enhancer; Ca

2+

, Calcium; cAMP, 3′,5′-cyclic adenosine monophosphate; FD, Fabry disease; FTD, Frontotemporal dementia; α-Gal A, α-galactosidase A; GAA, Acid α-glucosidase; GCase, Glucocerebrosidase; GD, Gaucher disease; G6PC, Glucose-6-phosphatase-α; GSDIa, Glycogen storage disease type Ia; GSDII, Glycogen storage disease type II; HD, Huntington's disease; HTT, Huntingtin; IP

3

, Inositol 1,4,5-trisphosphate; iPSC, Induced pluripotent stem cells; LD, Lafora disease; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MTMR14, Myotubularin related protein 14; mTORC1, Mechanistic target of rapamycin complex 1; NOS, Nitric oxide synthase; NPC, Niemann-Pick type C; 6-OHDA, 6-hydroxydopamine; PD, Parkinson's disease; PINK1, PTEN-induced kinase 1; PPAR, Peroxisome proliferator-activated receptor; PS1, Presenilin-1; Sap C, Saposin C; SMER, Small molecule enhancer of rapamycin; SphK, Sphingosine kinase; α-syn, α-synuclein; TDP-43, Transactive response DNA binding protein 43 kDa; TFEB, Transcription factor EB; VEGF, Vascular endothelial growth factor.

a

Protective effects of trehalose could be due to its chaperone-like ability to stabilize unfolded proteins (

Tanaka et al., 2004

).

b

Rapamycin was cytotoxic in GD iPSC-derived neurons (

Awad et al., 2015

).

c

Protective effects of metformin in LD may not be due to autophagy induction (

Berthier et al., 2016

).

![Impairment of autophagy in macromolecule storage disorders. Autophagy initiates by the formation of phagophore that expands and engulfs autophagic cargo to form autophagosome, which then matures to form autolysosome, either by initially fusing with the late endosome to form amphisome and then with the lysosome, or by directly fusing with the lysosome. Selective autophagic cargo includes aggregation-prone proteins, damaged mitochondria, lipid droplets and glycogen, as well as the autophagy receptor protein p62. LC3-II is used as a marker for autophagy as it remains on the autophagosome throughout its lifespan. Impairment of autophagy at distinct stages, such as autophagosome formation, cargo recognition and autophagosome maturation, caused due to the mutant proteins associated with various macromolecule storage disorders are indicated (red lines). Pharmacological induction of autophagy (blue arrow) by autophagy inducers (in blue box) exerts therapeutic benefits in transgenic models of many of these diseases. Abbreviations -- AD, Alzheimer's disease; FD, Fabry disease; FTD, Frontotemporal dementia; GD, Gaucher disease; GSDIa, Glycogen storage disease type Ia; GSDII, Glycogen storage disease type II; HD, Huntington's disease; LD, Lafora disease; mTOR, Mechanistic target of rapamycin; NPC, Niemann-Pick type C; PD, Parkinson's disease; PINK1, PTEN-induced kinase 1.](fcell-07-00179-g002){#F2}

The Role of Autophagy in Proteinopathies {#S3}
========================================

Accumulation of aggregated proteins in the brain causes neurodegenerative disorders that are collectively termed proteinopathies. Autophagy is the primary clearance mechanism for several aggregation-prone proteins, such as amyloid-β, α-synuclein and huntingtin, associated with Alzheimer's, Parkinson's and Huntington's disease, respectively ([@B114]; [@B102]); a process termed aggrephagy ([@B44]). The misfolded proteins that are targeted for autophagic degradation are ubiquitinated ([@B49]). The autophagy cargo receptors, p62 (SQSTM1) ([@B120]), NBR1 ([@B65]), optineurin ([@B67]), and TOLLIP ([@B85]), recruit the ubiquitinated cargo to the autophagosomes via their respective ubiquitin-binding domain and LC3-interacting region (LIR), whereas WDFY3 (also known as ALFY) acts as a scaffold for aggrephagy ([@B38]). Importantly, basal autophagy is critical for maintaining cellular homeostasis in post-mitotic neurons since abrogation of this process in normal mouse brain led to neurodegeneration ([@B51]; [@B66]); implicating that defective autophagy in neurodegenerative diseases is a major contributing factor. While autophagy dysfunction has been reported in almost all neurodegenerative diseases studied, few common proteinopathies where autophagy induction could be beneficial are discussed below.

Alzheimer's Disease and Tauopathies {#S3.SS1}
-----------------------------------

The commonest cause of progressive dementia is Alzheimer's disease (AD), characterized by abnormal metabolism of amyloid precursor protein (APP) that leads to the formation of extracellular senile plaques made of amyloid-β (Aβ) ([@B157]). Autophagy has a role in the generation, clearance and secretion of Aβ: Aβ has been suggested to be generated inside autophagosomes containing APP and the enzyme presenilin-1 (PS-1) that cleaves APP into Aβ; Aβ is degraded via autophagy; and Aβ is possibly secreted to extracellular space via autophagy where it forms plaques ([@B204]; [@B112]; [@B183]). In addition, autophagy is dysregulated at multiple stages depending on the gene mutation or the disease agent in AD ([@B114]). Mutations in *PS-1* gene, encoding for presenilin-1, impaired lysosomal acidification and function that blocked autophagic flux and prevented autophagosome maturation ([Figure 2](#F2){ref-type="fig"}) because PS1 is required for targeting of v-ATPase V~0~a~1~ subunit to the lysosomes for maintaining lysosomal pH ([@B75]; [@B197]). Indeed, accumulation of autophagosomes was seen in AD patient brain and in dystrophic neurites of PS1/APP mice ([@B13]). On the contrary, decrease in beclin-1, which regulates autophagosome formation, was found in the affected areas of AD patient brain that could be due to activated caspase-3 cleavage ([@B123]; [@B136]).

The presence of intracellular neurofibrillary tangles made of hyper-phosphorylated tau, a microtubule-associated protein, is another hallmark of AD and also for tauopathies including frontotemporal dementias (FTDs) ([@B168]). Mutant tau possibly retards autophagosome--lysosome fusion ([Figure 2](#F2){ref-type="fig"}) by impairing the retrograde axonal transport via the dynein/dynactin complex, as seen in FTD flies and mice ([@B88]; [@B17]). In addition, mutant tau colocalized with autophagic vesicles and the aggrephagy receptor protein p62 ([@B125]), and is likely degraded by autophagy ([@B9]; [@B191]).

Chemical or genetic upregulation of autophagy has been shown to be beneficial in transgenic models of AD and tauopathy. Rapamycin reduced Aβ plaques and tau tangles and rescued their pathology in APP/Tau/PS1 mutant (3xTg-AD) mice ([@B19]; [@B89]), APP/PS1 mutant mice ([@B56]), APP mutant mice ([@B169]), APOE4 mutant mice ([@B81]), FTD mice ([@B189]), and mutant tau mice ([@B118]; [@B57]; [@B163]) and *Drosophila* ([@B9]). One of the studies indicated that rapamycin was effective at early stages but not after the plaques and tangles were established ([@B89]). Likewise, the mTOR-independent autophagy enhancers, trehalose and carbamazepine, were also effective in clearing these toxic species and improving the disease pathology. Trehalose was beneficial in APP/PS1 mutant mice ([@B31]), APP mutant mice ([@B127]) and mutant tau mice ([@B135]; [@B154]), while carbamazepine in APP/PS1 mice ([@B179]), 3xTg-AD mice ([@B207]), and FTD mice ([@B189]). Additional autophagy-inducing compounds, such as SMER28, latrepirdine and gypenoside XVII (GP-17), were also shown to reduce Aβ levels and improve AD pathology ([@B182]; [@B170]; [@B101]). Genetically, overexpression of beclin-1 or TFEB reduced the levels and pathology of Aβ and tau in APP mutant mice ([@B123]) or in mutant APP/PS1 and mutant tau mice ([@B126]; [@B199]), respectively. As a likely consequence of disrupted autophagy, mitophagy is also affected in AD and is associated with mitochondrial dysfunction and bioenergetics deficits ([@B62]); whereas stimulation of mitophagy rescued the AD pathology in APP/PS1 mutant mice ([@B34]). Overall, multiple studies have pointed that stimulating autophagy could be beneficial in AD.

Parkinson's Disease {#S3.SS2}
-------------------

Parkinson's disease (PD) is the second most common neurodegenerative disorder characterized by motor deficits and cognitive decline ([@B6]). The commonly-mutated genes in familial PD encode for α-synuclein, PINK1, Parkin, and LRKK2, which have been shown to deregulate autophagy and mitophagy that contribute to the underlying neurodegeneration ([@B59]). The α-synuclein inclusions, also called Lewy bodies that are hallmark of PD, impaired autophagosome maturation without affecting lysosomal function ([@B178]). However, overexpression of α-synuclein (comparable to its gene multiplication in PD) in cells and transgenic mice suppressed autophagosome formation ([Figure 2](#F2){ref-type="fig"}) by mislocalization of ATG9 ([@B196]), and also by cytoplasmic retention of TFEB ([@B29]). Similar trafficking defect of ATG9 resulting in autophagy inhibition was seen with mutant VPS35, which causes an autosomal dominant form of PD ([@B206]). Additionally, mutations or depletion of PD-associated LRRK2, ATP13A2, and STY11 have been suggested to impair autophagy ([@B8]; [@B91]). The A53T and A30P point mutants of α-synuclein, however, mediated their toxic effects by impairing another form of autophagy called chaperone-mediated autophagy (CMA), which involves direct protein translocation across lysosomal membrane ([@B25]; [@B94]). Apart from the defects in autophagy and CMA in PD, compelling studies demonstrate a direct role of PD-associated mutant proteins in disrupting mitophagy. PINK1 and Parkin, which are commonly mutated in autosomal recessive juvenile PD, normally functions in maintaining mitochondrial quality control ([@B202]). Damaged mitochondria accumulate PINK1 on its outer membrane that recruits and activates the E3 ubiquitin ligase Parkin, which then ubiquitinates outer mitochondrial membrane proteins to initiate selective mitophagy ([@B124]). Pathogenic mutations in PINK1 and Parkin impair mitophagy ([Figure 2](#F2){ref-type="fig"}), which is associated with mitochondrial dysfunction, oxidative stress and mitochondrial DNA mutations ([@B7]; [@B46]; [@B107]; [@B14]).

Despite autophagy defects in PD, induction of autophagy could promote autophagic clearance of α-synuclein mutants ([@B194]), and has been shown to be beneficial in toxin-induced or transgenic mouse models of PD. Genetic activation of autophagy in α-synuclein transgenic mice or rats by Beclin-1 or TFEB overexpression, respectively, decreased α-synuclein levels and ameliorated neuropathology ([@B167]; [@B29]). Pharmacologically, rapamycin rescued disease progression, neuronal loss and mitochondrial dysfunction in MPTP-treated PD mouse models ([@B90]; [@B83]) and A53T α-synuclein transgenic mice ([@B5]), improved non-motor behavioral changes in 6-OHDA treated PD mouse model ([@B96]), and prevented dyskinesia in L-DOPA-treated mouse model of Parkinsonism ([@B143]). An additive effect of rapamycin and trehalose has been demonstrated in inducing autophagy, which was neuroprotective in MPTP-treated PD mice ([@B128]). Although trehalose could induce autophagy in human and other mammalian cell lines, mouse brain and iPSC-derived neurons, and has been robustly demonstrated to be effective against neurodegeneration by various studies ([@B53]), a recent report indicated that trehalose and other disaccharides could block autophagy and increase α-synuclein aggregation in immortalized human cells or rat cortical neurons ([@B201]). Nonetheless, trehalose and several other mTOR-independent autophagy inducers like verapamil, rilmenidine, valproate and calpastatin could enhance the clearance of α-synuclein mutants ([@B194]; [@B146]; [@B195]). Another autophagy inducer called 6-Bio, which acts by inhibiting mTORC1 signaling, enhanced α-synuclein clearance and ameliorated toxicity in MPTP-treated PD mice ([@B174]). Other autophagy-inducing compounds like metformin, piperlongumine and nilotinib were also protective in PD mice ([@B52]; [@B82]; [@B142]). Interestingly, retinoic acid derivatives such as AR7, GR1 and GR2 were shown to activate CMA for lowering α-synuclein levels and improving cell viability in a PD cell model expressing α-synuclein ([@B2]).

Huntington's Disease {#S3.SS3}
--------------------

Huntington's disease (HD) is a monogenic, autosomal dominant, neurodegenerative disorder characterized by motor and cognitive deficits. HD is caused by expansion of CAG repeats in *HTT* gene, resulting in polyglutamine-expanded mutant huntingtin protein that is aggregation-prone, cytotoxic ([@B211]), and is predominantly degraded by autophagy ([@B132]). Despite accumulation of autophagosomes in HD models ([@B61]; [@B122]), defective autophagy in HD is attributed to failure in autophagic cargo recognition. Mutant huntingtin impairs the recognition and recruitment of autophagic cargo by autophagosomes ([@B95]; [Figure 2](#F2){ref-type="fig"}), whereas wild-type huntingtin acts as a scaffold for recruiting autophagic proteins during selective autophagy such as aggrephagy and mitophagy ([@B115]; [@B140]). In addition, mutant huntingtin was also reported to perturb the axonal transport of autophagosomes that affected cargo degradation ([@B198]), which was also retarded by decreased dynein function that prevented the clearance of aggregation-prone proteins and augmented toxicity ([@B131]). Although mutant huntingtin is an established autophagy substrate ([@B152]), a recent study suggested that the conformation of mutant huntingtin dictates its ability to be cleared by autophagy. A toxic form of mutant huntingtin, recognized by the polyglutamine antibody 3B5H10, was found to lack Lys63 polyubiquitination that is essential to interact with p62/SQSTM1 for selective autophagy ([@B40]).

Nonetheless, pharmacological stimulation of autophagy enhances the clearance of mutant huntingtin preferentially over its wild-type counterpart ([@B132]), and the beneficial effects of autophagy induction are robustly demonstrated in cell, *Drosophila*, zebrafish and mouse models of HD ([@B151]). Amelioration of disease phenotypes in HD mice with autophagy-inducing compounds has been shown with rapamycin ([@B133]), trehalose ([@B177]), rilmenidine ([@B138]), calpastatin ([@B103]), and recently, with the anti-hypertensive drug felodipine at pharmacokinetics similar to its conventional application in humans ([@B161]); and also in HD fly models with SMERs ([@B147]), L-NAME ([@B149]), AUTEN-67 ([@B11]), AUTEN-99 ([@B68]), verapamil and valproate ([@B195]). A combination strategy for maximal stimulation of autophagy via mTOR inhibition and mTOR-independent routes was more effective in HD *Drosophila* than either approach ([@B150]). Overall, modulation of autophagy presents an attractive treatment option for HD patients.

The Role of Autophagy in Glycogen Storage Disorders {#S4}
===================================================

The selective clearance of carbohydrates such as glycogen via autophagy is termed glycophagy, which plays a crucial role in glucose homeostasis ([@B210]; [@B208]). The starch-binding domain-containing protein 1 (STBD1) has been identified as the receptor for selective glycophagy. STBD1 captures glycogen particles to autophagosomes by interacting with glycogen via its glycan-binding domain and with GABARAPL1 via its LIR motif ([@B55]; [@B209]). Improper glycophagy in glycogen storage disorders may contribute to the disease pathology ([@B208]).

Lafora Disease {#S4.SS1}
--------------

Lafora disease (LD) is an autosomal recessive myoclonus epilepsy characterized by neurodegeneration and intracellular inclusions of poorly-branched glycogen deposits called Lafora bodies ([@B113]). The commonly-mutated genes are *EPM2A* and *EPM2B* that encode laforin (phosphatase) and malin (E3 ubiquitin ligase), respectively, which together functions in the ubiquitin-proteasome system for promoting misfolded protein clearance ([@B43]). Knockout of these genes in mice inhibited autophagosome formation ([Figure 2](#F2){ref-type="fig"}), suggesting impairment of autophagy in LD that was also observed in patient fibroblasts ([@B1]; [@B24]; [@B33]). Mutant laforin suppressed autophagy by activating mTOR, whereas overexpression of wild-type laforin induced autophagy by inhibiting mTOR ([@B1]). Activation of mTOR in laforin-deficient cells further activated serum/glucocorticoid-induced kinase 1 (SGK1), and suppression of SGK1 activity could lower glycogen accumulation, inhibited mTOR and rescued the autophagy defect ([@B164]). Defective autophagic flux could lead to inefficient glycophagy and build-up of Lafora bodies that have neurotoxic effects ([@B33]); additionally, was also associated with impaired mitophagy, increased mitochondrial fragmentation and ROS production, and decreased ATP levels in laforin- and malin-deficient cells ([@B137]; [@B185]; [@B72]).

Expression of the wild-type or phosphatase-inactive mutant of laforin corrected glycogen branching, restored functional autophagy and reduced LB formation in *Epm2a^--/--^* mice ([@B45]), suggesting that abnormal glycogen accumulation in LD is likely via malfunction of cellular proteostasis and not due to glycogen dephosphorylation by laforin. These studies implicate defective autophagy in the pathogenesis of LD. Although a study has shown that metformin (AMPK activator and autophagy inducer) reduced LBs and neurodegeneration in *Epm2a^--/--^* mice, the beneficial effects of this compound were not attributed to autophagy induction because it did not affect autophagy *in vivo* ([@B10]). Nonetheless, since autophagy induction could have potential benefits by facilitating LB clearance and delaying neurodegeneration, further drug trials in LD mice are required to demonstrate whether this would be a therapeutic strategy.

Pompe Disease {#S4.SS2}
-------------

Pompe disease, also known as glycogen storage disease type II (GSDII), is an autosomal recessive glycogen storage disorder that affects muscle and nerve cells, and cause muscle weakness. GSDII is caused by mutations in the gene encoding for acid α-glucosidase (GAA), a lysosomal glycogen hydrolase. GAA normally degrades glycogen, but its mutations lead to glycogen accumulation in the lysosomes especially in cardiac and skeletal muscles ([@B130]). Accumulation of autophagosomes and autophagy substrates as well as vacuolization, enlarged lysosomes and improper lysosomal acidification were found in the myotubes of patients and primary myoblasts of *Gaa*-deficient mice ([@B42]; [@B129]; [@B175]; [@B108]); implicating a block in autophagy at late stage ([Figure 2](#F2){ref-type="fig"}). This is associated with inefficient mitophagy and impaired mitochondrial function ([@B79]). Moreover, since autophagy has been shown to influence GAA maturation and glycogen clearance ([@B108]; [@B210]; [@B208]), dysfunctional autophagy probably contributes to the pathogenesis of GSDII. In addition, mTOR activity was suppressed in the myotubes of *Gaa*-deficient mice where mTOR remained on the lysosomes even during starvation; and these effects including autophagosome accumulation were rescued by genetic reactivation of mTOR ([@B80]).

A common treatment for GSDII is the enzyme replacement therapy (ERT) ([@B30]), but its efficiency is variable and temporary that has been suggested to depend on the degree of autophagy dysfunction. This is because the trafficking and processing of the recombinant human GAA seems to be affected by autophagy ([@B41]; [@B109]). Autophagy activation by itself, either genetically via TFEB or TFE3 overexpression or pharmacologically with rapamycin, reduced glycogen and autophagosome load by promoting autophagosome maturation and lysosomal exocytosis in the myotubes of GSDII mice and patients and in iPSC-derived skeletal muscles ([@B3]; [@B99]; [@B108]; [@B166]; [@B93]; [@B153]). Therefore, combination of ERT with autophagy induction may be more effective. Indeed, combining rapamycin or CCI-779 treatment with ERT reduced muscle glycogen levels in GSDII mice more than either treatment alone ([@B3]). These studies highlight the therapeutic importance of autophagy in GSDII.

Von Gierke's Disease {#S4.SS3}
--------------------

Von Gierke's disease, also known as glycogen storage disorder type Ia (GSDIa), is an autosomal recessive disorder associated with hepatomegaly and kidney failure with symptoms including hypoglycemia, lactic acidosis and hyperlipidemia. GSDIa is characterized by glucose-6-phosphatase-α (G6PC) deficiency and decreased ability of the liver and kidney to break down glycogen into glucose that causes build-up of glycogen and triglycerides ([@B22]). Autophagy has been shown to be suppressed ([Figure 2](#F2){ref-type="fig"}) in hepatic cell and mouse (*G6pc^--/--^*) models of GSDIa possibly via activation of mTOR, inhibition of AMPK and reduced nuclear localization of TFEB ([@B35]). Likewise, increased acetyl coenzyme A in GSDIa could also have the same effect ([@B22]; [@B92]). Additionally, *G6pc^--/--^* mice also exhibited defective autophagy in the liver via downregulation of sirtuin-1 (SIRT1) ([@B21]), an enzyme which stimulates autophagy directly by deacetylation of ATG proteins and indirectly by deacetylation and activation of FoxO transcription factors that transactivate autophagy genes ([@B111]). Indeed, impaired autophagy in *G6pc^--/--^* mouse liver was attributed to increased acetylation of Atg5 and Atg7, decreased Atg5-Atg12 conjugation and reduced autophagosome formation ([@B21]).

Genetically, replacement of G6pc via recombinant adeno-associated virus (rAAV) vector improved hepatic glucose homeostasis and autophagic flux, and also restored SIRT1-FoxO signaling in *G6pc^--/--^* mice; although rAAV-mediated hepatic SIRT1 expression only rescued the autophagy abnormalities but not the metabolic defects ([@B21]). Pharmacologically, inducing autophagy with rapamycin reduced hepatic triglyceride, glycogen content and necrosis in the liver of *G6pc^--/--^* mice, diminished liver size and markers of liver damage in GSDIa dogs that were homozygous for an inactivating mutation in *G6pc* ([@B35]), and decreased ER stress in the kidney of *G6pc^--/--^* mice ([@B36]). In adult (older) mice, however, rapamycin could not rescue the defective autophagic flux in the liver but only marginally increased autophagosome formation ([@B21]). This study suggested that the differences between these two responses to rapamycin in the liver is thought to be due to the age of the mice as the hepatic gene expression regulated by mTOR differs depending on developmental stages and age ([@B15]; [@B21]). Furthermore, a pan-PPAR (peroxisome proliferator-activated receptor) agonist called bezafibrate, a lipid-lowering drug used for treating hyperlipidemia, was shown to reduce liver triglyceride and glycogen levels, induce mitochondrial biogenesis and improve autophagic flux in *G6pc^--/--^* mice ([@B193]). Since PPARα agonists such as Wy-14 643 and GW7647 could stimulate hepatic lipophagy and attenuate liver injury in mice and patients with acute liver failure ([@B58]; [@B74]), modulation of PPARα (a nutrient-sensing nuclear receptor) for inducing hepatic autophagy might represent a potential therapeutic target for the treatment of GSDIa.

The Role of Autophagy in Lipid Storage Disorders {#S5}
================================================

Autophagy is a major clearance route for intracellular lipids via a process termed lipophagy. This is evident from genetic ablation of autophagy in mice that increased triglyceride content and lipid droplets ([@B165]). However, the exact mechanism of selectively targeting the lipid droplets for autophagic degradation is not clear. In lipid storage disorders, malfunction of autophagy could thus contribute to the disease pathology ([@B192]).

Gaucher Disease {#S5.SS1}
---------------

Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder associated with neurological damage and hepatosplenomegaly. GD is characterized by mutations in *GBA1* gene encoding for glucocerebrosidase (GCase), an enzyme that hydrolyses glucosylceramide; and in rare cases by mutations in *PSAP* gene that leads to deficiency of the GCase activator, saposin C ([@B171]). Lysosomal accumulation of glucosylceramide and glucosylsphingosine in GD is thought to impair autophagy in the late stages ([Figure 2](#F2){ref-type="fig"}). Indeed, a block in autophagic flux associated with accumulation of autophagy substrates, ubiquitinated proteins, autophagosomes, and inefficient cathepsin activity, was seen in mice, flies, patient fibroblasts and iPSC-derived neuronal models of GD with GCase or saposin C deficiency ([@B173]; [@B186]; [@B180]; [@B117]; [@B37]; [@B4]; [@B27]). Defective mitophagy, mitochondrial dysfunction and oxidative stress were also found in GD that are likely consequences of impaired autophagy ([@B23]; [@B117]; [@B27]; [@B64]; [@B77]).

Interestingly, mutations in *GBA1* gene could induce neurodegeneration and correlated with increased risk of developing Parkinson's disease (PD) ([@B162]; [@B37]). This is because GCase and α-synuclein form a pathogenic loop wherein GCase deficiency (in GD) caused autophagic dysfunction and α-synuclein accumulation whereas overexpression of α-synuclein (in idiopathic PD) could disrupt GCase trafficking and activity ([@B97]; [@B155]; [@B32]; [@B87]). In a *Drosophila* model of neuronopathic GD, decreased mTOR activity and upregulation of the fly ortholog of mammalian TFEB was observed, which is thought to work as a compensatory mechanism for overcoming the autophagic block ([@B64]). Further inhibition of mTOR with rapamycin extended the life span and rescued the disease pathogenesis in GD flies ([@B64]). Contrary to these fly data, GD patient-specific iPSC-derived neurons exhibited downregulation of TFEB and lysosomal genes, where rapamycin treatment caused cell death ([@B4]). However, recombinant GCase rescued the defective autophagy and lysosomal depletion phenotypes in these disease-affected neurons; effects that were augmented by TFEB overexpression but not on its own ([@B4]). It is plausible that induction of autophagy in the presence of lysosomal dysfunction might be detrimental in disease-affected neurons, however, various mTOR-independent autophagy inducers need to be assessed in GD neurons to make this conclusion.

Niemann-Pick Type C Disease {#S5.SS2}
---------------------------

Niemann-Pick type C (NPC) disease is an autosomal recessive, lysosomal storage disorder associated with severe neurodegeneration and hepatosplenomegaly. It is caused by mutations in *NPC1* gene (95% cases; NPC1 disease) or *NPC2* gene (5% cases; NPC2 disease) ([@B187]). NPC1 (lysosomal cholesterol transporter) and NPC2 (lysosomal glycoprotein) proteins are suggested to facilitate cholesterol transport from the late endosomal/lysosomal compartments, and their mutations cause accumulation of unesterified cholesterol in the brain and other tissues ([@B60]; [@B71]). In NPC1 and NPC2 disease, a block in autophagic flux occurs due to impaired autophagosome maturation ([Figure 2](#F2){ref-type="fig"}) that results in build-up of autophagosomes and autophagic cargo ([@B145]; [@B73]; [@B50]) including defective mitophagy and mitochondrial function ([@B116]; [@B50]); although lysosomal function was not overtly compromised ([@B145]). Various mechanisms underlying autophagy defect in NPC1 disease have been described using mutant mice, patient fibroblasts and iPSC-derived neuronal models. These include failure in the SNARE machinery between autophagosomal Syntaxin-17 and late endosomal/lysosomal VAMP8 to prevent vesicle fusion ([@B39]; [@B145]), accumulation of sphingosine due to reduced sphingosine kinase activity and vascular endothelial growth factor (VEGF) levels ([@B73]), and depletion of lysosomal Ca^2+^ stores ([@B84]) that could affect autophagy via calcineurin or calpain ([@B195]; [@B98]). Interestingly, the most common NPC1 mutant (I1061T) is shown to be selectively degraded via ER autophagy (ER-phagy) and ER-associated protein degradation (ERAD) ([@B156]).

Of therapeutic relevance, autophagy inducers such as rapamycin and carbamazepine rescued the autophagy defect and improved cell viability in NPC1 iPSC-derived neuronal and hepatic cells, whereas trehalose, verapamil and BRD5631 were effective only in neurons ([@B86]; [@B70]). Although the multi-step route of autophagosome maturation was impaired in NPC1 disease, autophagy induction restored functional autophagic flux via the bypass mechanism enabling direct autophagosome--lysosome fusion; but this did not reduce the cellular cholesterol load ([@B145]). Strikingly, cholesterol-depleting agents like 2-hydroxypropyl-β-cyclodextrin, which has advanced in clinical trials, exhibited further impairment in autophagic flux, neurotoxic effects and adverse effects in animals ([@B121]; [@B145]; [@B188]). However, β-cyclodextrin derivatives such as methyl-β-cyclodextrin or β-cyclodextrin-threaded biocleavable polyrotaxanes could rescue the autophagy defect and enhance cholesterol clearance in NPC1 cells ([@B176]; [@B26]); although the effect on autophagy may not be their primary roles. Future directions may include efficacy studies of combination treatment involving autophagy inducer and a low-dose of cholesterol-depleting agent in mouse models.

Fabry Disease {#S5.SS3}
-------------

Fabry disease (FD) is a X-linked lysosomal storage disorder characterized by mutations in the *GLA* gene on the X chromosome encoding the lysosomal enzyme, α-galactosidase A (α-Gal A). FD is associated with impaired glycosphingolipid metabolism, lysosomal accumulation of a particular fat called globotriaosylceramide (Gb3) and multi-organ dysfunction ([@B47]). Autophagic flux is impaired in FD possibly due to defective autophagosome maturation ([Figure 2](#F2){ref-type="fig"}), as evident from accumulation of autophagosomes, lysosomes and autophagy substrates in patient fibroblasts, human podocyte model and α-Gal A deficient mice ([@B20]; [@B78]; [@B110]). However, build-up of autophagosomes may also occur due to increased biogenesis because FD podocytes displayed inhibition of mTOR and increased expression of autophagy initiation genes, *BECN1* and *GABARAP* ([@B78]; [@B16]). Autophagy dysfunction has been suggested to contribute to the neuropathological manifestations of FD, and also to podocyte damage in the kidneys resulting in end-stage renal disease that is a common cause of death in FD ([@B78]; [@B110]). In female patient fibroblasts, the disease severity correlated with the extent of impaired autophagy ([@B200]). The autophagy dysfunction is thought to interfere with the efficiency of ERT in FD podocytes ([@B20]); a phenomenon also reported in Pompe disease. Therefore, ERT coupled with induction of autophagy could be evaluated to improve the disease outcome.

Concluding Remarks {#S6}
==================

Autophagy is responsible for the maintenance of cellular homeostasis, and the functionality of this vital process is impaired in different ways in myriad macromolecule storage disorders associated with accumulation of aggregation-prone proteins, carbohydrates and lipids. Beyond the pathologies outlined in this review, autophagy has been implicated in several other macromolecule storage disorders including amyotrophic lateral sclerosis and polyglutamine diseases associated with build-up of aggregation-prone proteins ([@B102]), and neuronal ceroid lipofuscinosis associated with build-up of lipofuscin that are lipopigment materials made up of lipids and proteins ([@B158]). Defective autophagy reported in many such conditions has been suggested to contribute to the disease pathology, whereas in certain instances, stimulation of autophagy is beneficial which could reduce the macromolecular burden and prevent cytotoxicity. Autophagy inducing-compounds have been shown to attenuate the disease phenotype in various cell, fly and mouse models of these diseases where the lysosomal degradative capability if not overtly compromised. Modulation of autophagy by small molecules might thus represent an attractive therapeutic strategy in macromolecule storage disorders, but disease-specific treatments must be thoroughly researched because some of the conditions might require a combination of autophagy inducer and conventional therapy.
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